How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas

Non-Hodgkin’s lymphoma (NHL) is the sixth-most common cancer in the UK, accounting for around 13,700 new cases every year. Until the late 1990s, treatment relied on intensive chemotherapy, such as CHOP (cyclophosphamide–doxorubicin HCl–vincristine [Oncovin]–prednisone). The use of standard CHOP ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammed, Raihan, Milne, Artemis, Kayani, Kayani, Ojha, Utkarsh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398399/
https://www.ncbi.nlm.nih.gov/pubmed/30881167
http://dx.doi.org/10.2147/JBM.S190784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398399/
https://www.ncbi.nlm.nih.gov/pubmed/30881167
http://dx.doi.org/10.2147/JBM.S190784

Ejemplares similares